The Mantoux test or Mendel-Mantoux test (also known as the Mantoux screening test, tuberculin sensitivity test, Pirquet test, or PPD test for purified protein derivative) is a screening tool for tuberculosis (TB). It is one of the major tuberculin skin tests used around the world, largely replacing multiple-puncture tests such as the Tine test. The Heaf test was used until 2005 in the UK, when it was replaced by the Mantoux test. It is endorsed by the American Thoracic Society and Centers for Disease Control and Prevention. It was also used in the USSR and is now prevalent in most of the former Soviet states.
Tuberculin is a glycerol extract of the tubercle bacillus. Purified protein derivative (PPD) tuberculin is a precipitate of species-nonspecific molecules obtained from filtrates of sterilized, concentrated cultures. The tuberculin reaction was first described by Robert Koch in 1890. The test was first developed and described by the German physician Felix Mendel in 1908  It is named after Charles Mantoux, a French physician who built on the work of Koch and Clemens von Pirquet to create his test in 1907.
In 1939, M. A. Linnikova in the USSR created a modified version of PPD. In 1954, the Soviet Union started mass production of PPD-L, named after Linnikova.
A standard dose of 5 tuberculin units (TU - 0.1 ml) (The standard Mantoux test in the UK consists of an intradermal injection of 2 TU of Statens Serum Institute (SSI) tuberculin RT23 in 0.1 ml solution for injection.) is injected intradermally (between the layers of dermis) and read 48 to 72 hours later. This intradermal injection is termed the Mantoux technique. A person who has been exposed to the bacteria is expected to mount an immune response in the skin containing the bacterial proteins.
The reaction is read by measuring the diameter of induration (palpable raised, hardened area) across the forearm (perpendicular to the long axis) in millimeters. If there is no induration, the result should be recorded as "0 mm". Erythema (redness) should not be measured.
Classification of tuberculin reaction
The results of this test must be interpreted carefully. The person's medical risk factors determine at which increment (5 mm, 10 mm, or 15 mm) of induration the result is considered positive. A positive result indicates TB exposure.
- 5 mm or more is positive in
- An HIV-positive person
- Persons with recent contacts with a TB patient
- Persons with nodular or fibrotic changes on chest X-ray consistent with old healed TB
- Patients with organ transplants, and other immunosuppressed patients
- 10 mm or more is positive in
- Recent arrivals (less than five years) from high-prevalence countries
- Injection drug users
- Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes, hospitals, homeless shelters, etc.)
- Mycobacteriology lab personnel
- Persons with clinical conditions that place them at high risk (e.g., diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes, low body weight, etc.)
- Children less than four years of age, or children and adolescents exposed to adults in high-risk categories
- 15 mm or more is positive in
- Persons with no known risk factors for TB
(Note: Targeted skin testing programs should only be conducted among high-risk groups)
A tuberculin test conversion is defined as an increase of 10 mm or more within a two-day period, regardless of age. Alternative criteria include increases of 6, 12, 15 or 18 mm.
False positive result
TST (Tuberculin skin test) positive is measured by size of induration. The size of the induration which is considered to be a positive result depends on risk factors. For example, a low-risk patient must have a larger induration for a positive result than a high-risk patient. High-risk groups include recent contacts, those with HIV, those with chest radiograph with fibrotic changes, organ transplant recipients, and those with immunosuppression.
According to the Ohio Department of Health and US Department of Health, the Bacillus Calmette–Guérin (BCG) vaccine does not protect against TB infection. It does, though, give 80% of children protection against tuberculous meningitis and miliary tuberculosis. Therefore, a positive TST/PPD in a person who has received BCG vaccine is interpreted as latent TB infection (LTBI). Due to the test's low specificity, most positive reactions in low-risk individuals are false positives. A false positive result may be caused by nontuberculous mycobacteria or previous administration of BCG vaccine. Vaccination with BCG may result in a false-positive result for many years after vacination.
False positives can also occur when the injected area is touched, causing swelling and itching.
Another source of false positive results can be allergic reaction or hypersensitivity. Although rare, (about 0.08 reported reactions per million doses of tuberculin), these reactions can be dangerous and precautions should be taken by having epinephrin available.
False negative result
Reaction to the PPD or tuberculin test is suppressed by the following conditions:
- Infectious mononucleosis
- Live virus vaccine - The test should not be carried out within 3 weeks of live virus vaccination.
- Hodgkin's disease
- Corticosteroid therapy/Steroid use
- Immunological compromise - Those on immuno-suppressive treatment or those with HIV and low CD4 T cell counts, frequently show negative results from the PPD test.
This is because the immune system needs to be functional to mount a response to the protein derivative injected under the skin. A false negative result may occur in a person who has been recently infected with TB, but whose immune system hasn't yet reacted to the bacteria.
In case a second tuberculin test is necessary it should be carried out in the other arm to avoid hypersensitising the skin.
BCG vaccine and the Mantoux test
The role of Mantoux testing in people who have been vaccinated is disputed. The US recommends that tuberculin skin testing is not contraindicated for BCG-vaccinated persons, and prior BCG vaccination should not influence the interpretation of the test. The UK recommends that interferon-γ testing should be used to help interpret positive Mantoux tests, and repeated tuberculin skin testing must not be done in people who have had BCG vaccinations. In general, the US recommendation results in a much larger number of people being falsely diagnosed with latent tuberculosis, while the UK approach probably misses patients with latent tuberculosis who should be treated.
According to the US guidelines, latent tuberculosis infection diagnosis and treatment is considered for any BCG-vaccinated person whose skin test is 10 mm or greater, if any of these circumstances are present:
- Was in contact with another person with infectious TB
- Was born or has lived in a high TB prevalence country
- Is continually exposed to populations where TB prevalence is high
In cases of anergy, a lack of reaction by the body's defence mechanisms when it comes into contact with foreign substances, the tuberculin reaction will occur weakly, thus compromising the value of Mantoux testing. For example, anergy is present in AIDS, a disease which strongly depresses the immune system. Therefore, anergy testing is advised in cases where there is suspicion that anergy is present. However, routine anergy skin testing is not recommended.
Some people who have been infected with TB may have a negative reaction when tested years after infection, as the immune system response may gradually wane. This initial skin test, though negative, may stimulate (boost) the body's ability to react to tuberculin in future tests. Thus, a positive reaction to a subsequent test may be misinterpreted as a new infection, when in fact it is the result of the boosted reaction to an old infection.
Use of two-step testing is recommended for initial skin testing of adults who will be retested periodically (e.g., health care workers). This ensures any future positive tests can be interpreted as being caused by a new infection, rather than simply a reaction to an old infection.
- The first test is read 48–72 hours after injection.
- If the first test is positive, consider the person infected.
- If the first test is negative, give a second test one to three weeks after the first injection.
- The second test is read 48–72 hours after injection.
- If the second test is positive, consider the person infected.
- If the second test is negative, consider the person uninfected.
A person who is diagnosed as "infected" on two-step testing is called a "tuberculin reactor". The US recommendation that prior BCG vaccination be ignored results in almost universal false diagnosis of tuberculosis infection in people who have had BCG (mostly foreign nationals).
As a replacement for the Mantoux test, several other tests are being developed. The QuantiFERON-TB Gold blood test measures the patient’s immune reactivity to the TB bacterium, and is useful for initial and serial testing of persons with an increased risk of latent or active tuberculosis infection. Guidelines for its use were released by the CDC in December 2005. QuantiFERON-TB Gold is FDA-approved in the United States, has CE Mark approval in Europe and has been approved by the MHLW in Japan.
The Heaf tuberculin skin test was used in the United Kingdom, but discontinued in 2005.
The equivalent Mantoux test positive levels done with 10 TU (0.1 ml at 100 TU/ml, 1:1000) are
- <5 mm induration (Heaf 0-1)
- 5–15 mm induration (Heaf 2)
- >15 mm induration (Heaf 3-4)
|Wikimedia Commons has media related to Mantoux test.|
- F. Mendel. Therapeutische Monatshefte, Berlin, 1903, 16: 177. Die von Pirquet'sche Hautreaktion und die intravenöse Tuberkulinbehandlung.Medizinische Klinik, München, 1908, 4: 402-404.
- DTBE - Mantoux TB Skin Test Faciliator Guide - Part 1: Administering
- "Immunisation", UK government, Department of Health
- From the CDC team of the CDC team at the Saskatchewan Lung Association, photos of a PPD bump.
- Mantoux Test in eac.int.
- Menzies, Dick (1 January 1999). "Interpretation of Repeated Tuberculin Tests". American Journal of Respiratory and Critical Care Medicine 159 (1): 15–21. doi:10.1164/ajrccm.159.1.9801120. PMID 9872812.
- Information also from ODH lecture at the Ohio State University 5/24/2012.
- Starke JR (Jul 1996). "Tuberculosis Skin Testing: New Schools of Thought". Journal of the American Academy of Pediatrics 98 (1): 123–125. ISSN 0031-4005. PMID 8668383.
- Chaturvedi N, Cockcroft A (1992). "Tuberculosis screening among health service employees: who needs chest X-rays?". J Soc Occup Med 42 (4): 179–82. doi:10.1093/occmed/42.4.179.
- James E. Froeschle, Frederick L. Ruben, and A. Michael Bloh (2002). "Immediate Hypersensitivity Reactions after Use of Tuberculin Skin Testing". Clinical Infectious Diseases 34 (1): e12–e13. doi:10.1086/324587.
- Tuberculin and Anergy Testing in HIV-Seropositive and HIV-Seronegative Persons - Markowitz et al. 119 (3): 185 - Annals of Internal Medicine
- Office of Health and Human Services. "Booster Phenomenon". Retrieved 2008-07-02.
- Guidelines for Using the QuantiFERON-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States